We investigated the role the MTP Ϫ493G/T gene polymorphism in determining the apoB-100 secretion pattern and LDL heterogeneity in healthy human subjects. Groups of carriers of the T and the G variants (n ϭ 6 each) were recruited from a cohort of healthy 50-yr-old men. Kinetic studies were performed by endogenous [ 2 H3]leucine labeling of apoB and subsequent quantification of the stable isotope incorporation. apoB production rates, metabolic conversions, and eliminations were calculated by multicompartmental modeling (SAAM-II). LDL subfraction distribution was analyzed in the entire cohort (n ϭ 377). Carriers of the MTP Ϫ493T allele had lower plasma LDL apoB and lower concentration of large LDL particles [LDL-I: 136 Ϯ 57 (TT) vs. 175 Ϯ 55 (GG) mg/l, P Ͻ 0.01]. Kinetic modeling suggested that MTP Ϫ493T homozygotes had a 60% lower direct production rate of intermediate-density lipoprotein (IDL) plus LDL compared with homozygotes for the G allele (P Ͻ 0.05). No differences were seen in production rates of large and small VLDL, nor were there any differences in metabolic conversion or elimination rates of apoB between the genotype groups. This study shows that a polymorphism in the MTP gene affects the spectrum of endogenous apoB-containing lipoprotein particles produced in humans. Reduced direct production of LDL plus IDL appears to be related to lower plasma concentrations of large LDL particles.
intermediate-density lipoprotein; low-density lipoprotein; apolipoprotein B; very-low-density lipoprotein secretion; lipidation; microsomal triglyceride transfer protein THE ASSEMBLY AND SECRETION of apolipoprotein B (apoB)-containing lipoproteins by the human liver is a complex process that is regulated at different levels by a variety of factors such as substrate availability, insulin concentration, and the activity or abundance of the proteins involved. It has been postulated that a major determinant of the lipoprotein heterogeneity observed in plasma is due to the heterogeneity in the production rate of apoB-containing lipoprotein (26) . Increased influx of nonesterified fatty acids (NEFA) and uptake of triglycerides contained in remnant lipoproteins promotes the secretion of large VLDL particles by the hepatocyte. This process is rapidly and significantly inhibited by insulin, which also reduces the substrate availability of NEFA (2) . As such, a direct inhibitory effect on the secretion process of VLDL has also been described in vitro and in vivo (12, 25) . Little is known of the mechanisms regulating the synthesis and secretion of the smaller apoB-containing lipoproteins small VLDL, intermediate-density lipoprotein (IDL), or even LDL. Neither substrate availability nor insulin appears to regulate their production (25) . Rather, mechanisms intrinsic to the hepatocyte may determine the production of small apoB-containing lipoproteins, but very little is known of the genetic regulation of apoB secretion. The activity state of the microsomal triglyceride transfer protein (MTP) may provide such a mechanism, due to its strategic role in the production process. Studies in isolated hepatocytes have shown that MTP is important during several steps in the assembly and secretion of apoB-containing lipoproteins (9) . During the translation of the apoB peptide, MTP transfers lipids to the primordial apoB particle and may, therefore, determine its degree of lipidation (9) . Later, MTP also determines the maturation of the nascent particle by taking part in the final lipidation process, which probably involves fusion between the primordial particle and a preformed lipid droplet, the so-called "second step."
There is evidence for a link between polymorphisms in the MTP gene and the LDL cholesterol concentration. Some recent studies have shown a link between the presence of the MTP-493T variant and low LDL cholesterol (17, 20, 21) , but conflicting or negative evidence has also been observed (5, 15) . One possible explanation for the discrepant results is an interaction with visceral obesity (30) . It is also possible that there is an interaction with the LDL receptor gene or the hepatocyte cholesterol homeostasis, as the phenotype of the MTP polymorphism switches from modulating LDL concentrations to plasma triglyceride (VLDL) concentrations in subjects with familial hypercholesterolemia (24) .
We hypothesize that a common variant in the MTP gene, with presumed effects on the activity state of the MTP protein, is an important regulator of the size spectrum of apoB-containing lipoproteins produced from the human liver and that this might determine some of the aspects of the lipoprotein heterogeneity seen in plasma. To study this we recruited geneti-cally defined healthy carriers of the MTP Ϫ493G/T variants and performed apoB turnover studies using endogenous stable isotope labeling to define the production, conversion, and elimination rates of apoB-containing lipoproteins. In addition, we determined the genotype-phenotype relationship between the MTP gene promoter variants and LDL subclass distribution within the entire cohort from which the turnover study subjects were recruited.
METHODS

Subjects.
A total of 377 healthy 50-year-old men living in Stockholm County, Sweden, were recruited from a randomized populationbased screening program. Exclusion criteria were chronic disease of any kind, a history of coronary heart disease or arterial thromboembolic disease, and continuous treatment with antihypertensive or lipid-lowering agents. Only men of northern European descent were included.
The LDL subfraction distribution was measured in the entire cohort. Data on these subjects have recently been presented in relation to genetic variation in the lipoprotein lipase (LPL), hepatic lipase (HL), cholesteryl ester transfer protein (CETP), and apoE genes (28) . A total of 12 subjects participated in the turnover studies. Four of these subjects were recruited from a previous collection of healthy men and performed according to the same principles and within the same geographic area (31) . This was done to increase the total number of potential volunteers for the study (there are ϳ6 homozygous carriers of the MTP Ϫ493T variant for every 100 people). A total of 20 homozygous carriers for the T variant were first invited; 11 were willing, and six were selected to participate. Subjects homozygous for the G variant (ϳ50 for every 100 people) were then approached to match the six T carriers. After completion of the study, the genotypes of the 12 subjects were checked by sequencing. It turned out that one subject who was first allocated an MTP Ϫ493TT genotype was actually a heterozygote. This subject was still included in the TT group. The study was approved by the Ethics Committee of the Karolinska Hospital, and all subjects gave informed consent to participation.
Genotyping. The MTP Ϫ493G/T polymorphism was genotyped by restriction isotyping as described (17) . All amplifications were performed in a 25-l reaction mix containing 100 ng of genomic DNA, 0.8 M of each primer, 2 mM of each dNTP (Boehringer Mannheim, Mannheim, Germany), 1 U Taq polymerase (SDS Promega, Madison, WI), 50 mM KCl, 10 mM Tris ⅐ HCl, and 0.1% Triton X-100. Subjects were also genotyped for the apoE-2/3/4 polymorphism (13, 28) .
Turnover protocol. Subjects arrived at the Clinical Research Unit in the morning after a 10-h fast. Blood samples were taken at times 0, 0. 16, 0.33, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24 , and 36 h and daily after that for 14 days. A bolus injection of 0.7 mg/kg body wt of trideuterated [ 2 H3]leucine was given at time 0 followed by an infusion of 0.7 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 for 10 h. Only noncaloric drinks were allowed during the first 10 h. Then, a light snack was provided, and the subjects went home. The 15-h sample was taken at home. The subjects were asked to maintain a regular life for the following fortnight, which comprised a habitual diet without extremes, limited alcohol intake, and no more exercise than was usually taken.
Kinetic modeling. The change in tracer-to-tracee ratio with time of subfraction (Sf) 60 -400 (VLDL 1), Sf 20 -60 (VLDL2), IDL, and LDL apoB together with the apoB pool size was used to derive the kinetic parameters by using the simulation analysis and modeling (SAAM) program II, version 1.1.1, for Windows (SAAM Institute, Seattle, WA). The multicompartmental model has been described before ( Fig. 1) (8) . It has been applied to various metabolic and hyperlipidemic conditions without modification, which indicates that it can provide solutions to normal as well as extreme metabolic situations (8, 10, 11). The same model was applicable in this study without any need for modification, despite the fact that some of the subjects studied here had lower apoB concentrations than the model had been exposed to before.
The input is through compartment 1, which represents plasma. Compartment 2 is an intracellular equilibrium compartment, and compartments 3 and 4 are slow-turnover compartments. Compartment 5 is a delay compartment that was set to 30 min, equivalent to the assembly and secretion process in the liver, from which VLDL 1, VLDL2, IDL, and LDL were allowed to enter the system. For VLDL1, VLDL2, and IDL material was allowed to leave the compartment by a rapid or a slow exit, as well as be transferred to the next compartment further down in the cascade. LDL had one exit and one presumed extravascular equilibration compartment. The model was a priori identifiable, provided that the numbers of unknowns were restricted by locking certain parameters. These were k (7, 6) (12, 9) , and k(13,14) ϭ 2.5 ϫ k (14, 13) . The exchange constant between extra-and intravascular LDL compartment is arbitrary, and it is based on the assumed proportion of LDL residing in the plasma compartment.
Plasma volumes were calculated using an algorithm based on age and weight as input variables (6) . The pool sizes were calculated as the product of the plasma concentration and the plasma volume.
Lipid, lipoprotein, and apolipoprotein methods. Venous blood samples were drawn into precooled sterile tubes (Vacutainer; BectonDickinson) containing Na 2EDTA (final concentration 4 mmol/l), and plasma was recovered by low-speed centrifugation (1,750 g, 20 min, 1°C). Phenylmethylsulfonyl fluoride (10 mmol/l, dissolved in isopropanol) and aprotinin (1.4 g/l Trasylol, Bayer) were immediately added to the isolated plasma to final concentrations of 10 mol/l and 28 g/ml, respectively. A conventional ␤-quantification was made to measure the concentrations of major plasma and lipid and lipoproteins (4) . Fractions of VLDL 1, VLDL2, IDL, and LDL were isolated by density gradient ultracentrifugation (18) . After the removal of the VLDL2 fraction, the tube was sliced 19 mm from the top to isolate IDL. An additional slice of 57 mm from the top was made to isolate LDL. The apoB content in each fraction in VLDL1, VLDL2, and IDL . Compartments 6, 8, 9, 11 , and 13 form a delipidation chain, and compartments 7, 10, and 12 represent theoretical "remnant populations" of particles that are cleared relatively slowly from each density interval. IDL apoB, which is largely restricted to the plasma space, is modeled as 2 intravascular compartments, one of which is delipidated to LDL (compartment 11). LDL apoB, on the other hand, is represented by a single plasma compartment. A biexponential nature of the [ 2 H3]leucine decay curve is accounted for by extravascular exchange with the plasma compartment.
was determined by analytical SDS-PAGE (16) . The apoB content in LDL was equated to the total protein content determined by the Lowry et al. method (22) , with the addition of 1% SDS to all reagents. apoB was physically isolated by isopropanol extraction (14) for hydrolysis and subsequent analysis of isotope enrichment by gas chromatography-mass spectrometry (8) .
Protein pellets were hydrolyzed to amino acids at 110°C for 24 h in 6 M HCl and evaporated to dryness. Amino acids were finally isolated by cation exchange chromatography, using Dowex AG 50W-X8 resin (H ϩ form, 50 -100 mesh; Bio-Rad, Richmond, CA) and eluted in 4 M NH4OH. Samples were analyzed for isotope enrichments as previously described (8) .
LDL subfraction distribution. The plasma concentrations of LDL subfractions were determined by subjecting a sample of isolated LDL to high-resolution, nondenaturing polyacrylamide gradient (3-7.5%) gel electrophoresis (GGE). A detailed description of the GGE procedure has been published (29) . This procedure provides quantification of the plasma concentrations of predefined subfractions of LDL with the following cutoffs: LDL-I (27.0 -25.0 nm), LDL-II (25.0 -23.5 nm), LDL-III (23.5-22.5 nm), and LDL-IV (22.5-21.0 nm).
Statistics. Statistical calculations were performed by using the statistical software package StatView (SAS, Cary, NC). Skewed variables were log 10-transformed before analysis. One-way analysis of variance and Scheffé's post hoc test were used to compare differences between means. Statistical differences in kinetic parameters between the groups were calculated using the Mann-Witney U-test.
RESULTS
Plasma lipids and body mass index in the cohort.
The average total plasma concentration of cholesterol and triglycerides was within the expected range for a healthy population ( Table 1 ). The body mass index (BMI) was marginally lower among the subjects selected for the turnover study (Table 1  compared with data in Table 2 , not statistically significantly different).
Characteristics of subjects taking part in the turnover study. The genotypic groups were well matched for age and BMI but displayed an expected wide range of apoB concentrations in the VLDL 1 and VLDL 2 fractions, with a narrower range observed in the IDL and LDL fractions ( Table 2 ). There was no statistically significant difference between the groups, but some of the lower LDL apoB values were found among the MTP Ϫ493T carriers. LDL apoB was closely correlated with LDL cholesterol (r ϭ 0.82, P Ͻ 0.01, n ϭ 12). The fasting apoB concentrations in VLDL 1 , VLDL 2 , IDL, and LDL were stable over the study period (data not shown). apoE genotypes were balanced between the groups.
Production, conversion, and elimination of apoB-containing lipoproteins. Pool sizes and production rates of VLDL 1 and VLDL 2 were similar between the groups (Table 3 ). The rate constants for each individual derived from the multicompartmental modeling is shown in Table 4 . Except for one subject the direct catabolism of VLDL 1 was in the same order of magnitude, and so was the transfer of material from VLDL 1 to VLDL 2 (Table 3) . IDL and LDL apoB direct production was generally much lower than the direct production of VLDL. The IDL and LDL direct production tended to be lower in the MTP Ϫ493T carriers. Therefore, the production rates of IDL and LDL apoB were added to give an estimate of the direct secretion of the non-triglyceride-rich apoB-containing lipoproteins. This showed that the production rate was only one-third in the carriers of the MTP Ϫ493T variant compared with the Sf, subfraction. Production rates, pool sizes, catabolic rates, and transfer rates were calculated exactly as described previously (8). Table 4 . Individual rate constants for the major steps in the multicompartmental model Subjects d (6, 5) d (8, 5) d (11, 5) d (13, 5) k (8, 6) k (11, 9) k (13, 11) The IDL and LDL apoB kinetic curves of two representative subjects (subjects 2 and 12), one for each genotypic group, are shown in Fig. 2 . The subjects were chosen because their IDL and LDL apoB kinetic parameters were the closest to the respective mean for each group. It is noted that the rise of the incorporation of label into the LDL apoB is significantly more rapid in the GG carrier than in the TT carrier. This could be a sign of lower direct secretion of LDL apoB in the TT carrier.
De novo production of LDL has been questioned as a phenomenon as such (27) . Therefore, we wanted to test if our data were compatible with an alternative kinetic model originally explored by Demant et al. (8) , which involves a rapid conversion of VLDL to LDL to account for the rapid appearance of label in the LDL compartment. Although the data seemed to fit this model equally well for subjects carrying the MTP Ϫ493T variant, we were unable to achieve a good fit in some of the subjects carrying the G variant. This was particularly true for the subjects expressing the higher LDL/IDL direct production, according to the core model described in this work.
LDL subfractions. In the entire cohort (n ϭ 377), the allele frequency of the less common MTP promoter variant (Ϫ493T) was 0.25. Genotype frequencies were in Hardy-Weinberg equilibrium. In general, the LDL-II subfraction contained ϳ50% of total LDL apoB, whereas the small dense LDL (LDL-III and -IV) comprised, on average, 33% of total LDL apoB.
Mean plasma concentrations of total LDL apoB and apoB in the LDL subfractions are shown according to the MTP Ϫ493G/T genotypes in Table 5 . Subjects homozygous for the uncommon MTP Ϫ493T allele had significantly decreased plasma LDL apoB concentration (740 Ϯ 191 vs. 861 Ϯ 185 mg/l, P Ͻ 0.05) compared with MTP Ϫ493G homozygotes. The decrease in plasma LDL apoB concentration was most pronounced in the LDL subfractions containing larger, more buoyant LDL (LDL-I and -II), with a significant reduction in the plasma concentration of LDL-I (136 Ϯ 57 vs. 175 Ϯ 55 mg/l, P Ͻ 0.001) in MTP Ϫ493T homozygotes compared with MTP Ϫ493G homozygotes. There was no corresponding increase in the plasma concentration of small dense LDL particles, nor was there a significant shift in the LDL peak particle size. There was no statistically significant difference in plasma triglycerides between the groups.
DISCUSSION
Here, we demonstrate that the MTP Ϫ493G/T polymorphism modulates the secretion rate of apoB-containing lipoproteins in that the direct production of IDL and LDL was reduced in carriers of the T variant. We have previously shown that this genetic variant is associated with lower plasma LDL cholesterol concentrations (17, 20) , and here it appears that this is due to a lower abundance of the larger LDL particles.
We can only speculate as to how the MTP Ϫ493T variant reduces the production of the smallest apoB-containing lipoproteins. Very little is known regarding the molecular effect of this polymorphism, but initial studies using in vitro constructs of the MTP promoter have indicated that the T variant enhances the transcriptional activity. In contrast, a recent quantification of MTP mRNA content in myocardial tissue showed that T variant carriers had significantly less of the transcript than G variant carriers (21) . It could be hypothesized that the low MTP activity seen in T variant carriers does not sufficiently fill the smallest apoB-containing particles. Hence, poorly lipidated lipoproteins would then undergo intracellular degradation (1), and we postulate that the smallest lipoproteins would be the most vulnerable in this process. It could also be that a lower number of particles in the lipidation cascade favor lipidation of the few remaining particles, consequently observed as a lower number of small particles being secreted. Alternatively, the MTP Ϫ493G/T polymorphism is in linkage disequilibrium with another yet unknown genetic variant that influences MTP activity or function. We have previously reported (23) on the phenotype of this genetic variant on postprandial apoB-48 concentrations. In that study, the smallest apoB-48-containing lipoproteins increased almost 100% in homozygous carriers of the T variant compared with the G variant. We have no explanation for this apparent paradox in relation to the present results, but it is quite likely that the role of MTP differs between the VLDL production by the hepatocyte and the chylomicron production by the enterocyte.
Few previous studies have examined the role of common genetic variability on apoB production. In a study by Watts et al. (32) , a cohort of 29 obese subjects who had undergone stable isotope turnover studies to determine the VLDL apoB production rate were genotyped for variants in the apoB, apoE, CETP, HL, and MTP genes. They concluded that variation in the apoB and CETP genes modulated the VLDL production. The effect of the MTP Ϫ493G/T gene variant was not statistically significant on its own, but in combination with other genetic variants, carriers of the MTP Ϫ493T variants tended to have lower VLDL apoB production rate, which is a finding in the same direction as ours. The production rates of the nontriglyceride-rich apoB-containing lipoproteins (IDL and LDL) were not estimated in that study. In addition, variation in the apoB gene has been associated with the fractional clearance of LDL, but the original study does not provide a potential mechanism (7) .
Genetic factors determining the LDL subclass distribution are overwhelmed by the strong association between plasma triglycerides and the relative abundance of small dense LDL (3). Still, there is strong evidence that the LDL subclass distribution is under genetic influence, although the major genes for this regulation remain unknown (19) . Variability in a range of genes coding for proteins that are known to regulate the compositional characteristics of LDL is only weakly associated with LDL heterogeneity (28) . However, very little is known of how variability in genes involved in apoB secretion influences LDL heterogeneity. The MTP gene could be such a candidate, but the present results appear to show that the impact of MTP genetic variability is rather limited. Instead, the interesting link between the apoB production rate of the various subclasses of apoB-containing lipoproteins and LDL heterogeneity is on a physiological level. The consequence of reduced direct production of IDL and LDL, as observed in the MTP Ϫ493TT carriers, seems to lower the absolute abundance of large LDL. This relationship suggests that a certain proportion of the large LDL particles in plasma are nascent particles that have not been formed from VLDL precursors. From a clinical point of view the abundance of small dense LDL has been associated with atherosclerosis, but these particles are likely to be formed as a consequence of sequential lipid exchanges and lipolytic processes of the LDL triglycerides, cholesteryl esters, and phospholipids. Here, we are most likely dealing with an issue of altered direct production of nascent apoB-containing lipoproteins, which does not appear to affect the abundance of small dense LDL.
A limitation of this study is the small size of the groups taking part in the turnover study. However, it should be recognized that the "recruit-by-genotype" design is used to address a very specific issue and that the results are biologically plausible and consistent in the context of the larger cohort studied. Possibly, the heterogeneity within the study groups could have been reduced if the participants had been on strict diets or observed under stricter metabolic conditions, but such conditions are difficult to maintain over a 14-day period. The VLDL apoB kinetic data showed a high degree of heterogeneity, but this is normally seen with the use of multicompartmental modeling. In this study the participants were asked to avoid excesses in the form of alcohol intake, special meals, and particularly strenuous exercise that was not part of regular life.
In summary, this study shows that the pattern of apoB secretion from the human liver is partly genetically regulated. In particular, the direct production of the smallest apoBcontaining lipoproteins (IDL and LDL) appears to be influenced by variability in the MTP gene, and this has direct consequences for the LDL subclass pattern observed in plasma.
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